By 2026-07-16: Billing team must implement mandatory precertification workflow for all Aetna commercial plans before submitting any claims for the following medications: Armlupeg, Fulphila, Fylnetra, Neulasta, Nyvepria, Rolvedon, Ryzneuta, Stimufend, Udenyca, Ziextenzo (long-acting G-CSFs); Neupogen, Filkri, Nivestym, Nypozi, Releuko, Zarxio (short-acting G-CSFs); Granix; and Leukine. Update billing system to BLOCK claim submission without prior authorization. Providers must submit precertification requests to Aetna at (866) 752-7021 or fax (888) 267-3277 before administering medication. Front desk staff must add precertification checklist to encounter forms. Claims submitted without precertification approval will be denied. Update encounter templates to document: (1) chemotherapy regimen and FN risk percentage, (2) patient risk factors if applicable, (3) whether this is primary or secondary prophylaxis or febrile neutropenia treatment, and (4) confirmation that no other CSFs are being used in the same cycle. Train billing staff to verify that requested medication meets ONE of the three FN risk tier criteria or falls under approved "Other Indications" (acute myeloid leukemia, agranulocytosis, aplastic anemia, CAR T-cell toxicities, chronic myeloid leukemia, glycogen storage disease type 1, hairy cell leukemia, acute radiation syndrome, myelodysplastic syndrome, HIV/AIDS-related neutropenia, renal transplant neutropenia, severe chronic neutropenia, or stem cell transplantation).